PE20081377A1 - Compuestos de tiazol pirazolopirimidina - Google Patents
Compuestos de tiazol pirazolopirimidinaInfo
- Publication number
- PE20081377A1 PE20081377A1 PE2007001271A PE2007001271A PE20081377A1 PE 20081377 A1 PE20081377 A1 PE 20081377A1 PE 2007001271 A PE2007001271 A PE 2007001271A PE 2007001271 A PE2007001271 A PE 2007001271A PE 20081377 A1 PE20081377 A1 PE 20081377A1
- Authority
- PE
- Peru
- Prior art keywords
- thiazol
- propyl
- ethyl
- compounds
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE TIAZOL PIRAZOLOPIRIMIDINA DE FORMULA (I), EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE ETILO O n-PROPILO; R3 ES H, Cl, Br, METILO, TRIFLUOROMETILO O METOXI; R4 ES H, Br, RaRbN-, METOXIMETILO, PIRIDIN-4-ILO, MORFOLIN-4-ILO, ENTRE OTROS. SON SELECCIONADOS: 7-(1-ETIL-PROPIL)-2,5-DIMETIL-3-(4-METIL-TIAZOL-5-IL)-PIRAZOLO[1,5-a]PIRIMIDINA, 3-(2,4-DIBROMO-TIAZOL-5-IL)-7-(1-ETIL-PROPIL)-2,5-DIMETIL-PIRAZOLO[1,5-a]PIRIMIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CRF1 (FACTOR DE LIBERACION DE CORTICOTROPINA), POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS, TRASTORNOS PSIQUIATRICOS, NEUROENDOCRINOS, TRASTORNOS NEUROLOGICOS Y SINDROME METABOLICO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82626406P | 2006-09-20 | 2006-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081377A1 true PE20081377A1 (es) | 2008-09-18 |
Family
ID=38924802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001271A PE20081377A1 (es) | 2006-09-20 | 2007-09-20 | Compuestos de tiazol pirazolopirimidina |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US8030304B2 (es) |
| EP (1) | EP2094709B1 (es) |
| JP (1) | JP5161226B2 (es) |
| KR (1) | KR101088239B1 (es) |
| CN (1) | CN101516887B (es) |
| AR (1) | AR062886A1 (es) |
| AT (1) | ATE481405T1 (es) |
| AU (1) | AU2007297421B2 (es) |
| BR (1) | BRPI0717023B8 (es) |
| CA (1) | CA2663511C (es) |
| CL (1) | CL2007002693A1 (es) |
| CR (1) | CR10682A (es) |
| CY (1) | CY1110854T1 (es) |
| DE (1) | DE602007009305D1 (es) |
| DK (1) | DK2094709T3 (es) |
| EA (1) | EA015179B1 (es) |
| ES (1) | ES2350282T3 (es) |
| HR (1) | HRP20100516T1 (es) |
| IL (1) | IL197614A (es) |
| MA (1) | MA30798B1 (es) |
| MX (1) | MX2009003125A (es) |
| MY (1) | MY146388A (es) |
| NO (1) | NO20091489L (es) |
| NZ (1) | NZ575572A (es) |
| PE (1) | PE20081377A1 (es) |
| PL (1) | PL2094709T3 (es) |
| PT (1) | PT2094709E (es) |
| RS (1) | RS51545B (es) |
| SI (1) | SI2094709T1 (es) |
| TN (1) | TN2009000095A1 (es) |
| TW (1) | TWI402269B (es) |
| UA (1) | UA96458C2 (es) |
| WO (1) | WO2008036579A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DK2350079T3 (da) * | 2008-10-02 | 2012-12-17 | Lilly Co Eli | Thiazolylpyrazolopyrimidinforbindelser som syntetiske mellemprodukter og dertil relaterede syntetiske fremgangsmåder |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6585625B2 (ja) | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| PL236355B1 (pl) * | 2015-04-02 | 2021-01-11 | Celon Pharma Spolka Akcyjna | Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 |
| CN109906222B (zh) | 2016-09-07 | 2023-08-01 | 加利福尼亚大学董事会 | 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂 |
| EP3628005A4 (en) * | 2017-08-14 | 2021-01-20 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| CN110997667A (zh) * | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| CN112423747A (zh) * | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| CN109134481B (zh) * | 2018-08-07 | 2021-05-14 | 中山大学 | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| TW202446384A (zh) | 2018-12-07 | 2024-12-01 | 美商紐羅克里生物科學有限公司 | 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式 |
| AU2020318970A1 (en) * | 2019-07-19 | 2022-03-03 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
| CN114502162B (zh) | 2019-09-27 | 2025-03-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| US20230065034A1 (en) * | 2019-12-04 | 2023-03-02 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| GR1010096B (el) * | 2020-07-02 | 2021-10-08 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, | Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης |
| CN118948857A (zh) * | 2020-08-12 | 2024-11-15 | 云杉生物科学公司 | 用于治疗多囊卵巢综合征的方法和组合物 |
| US20240024330A1 (en) | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| WO2022197798A1 (en) | 2021-03-19 | 2022-09-22 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
| EP4402142A4 (en) * | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2023163945A1 (en) * | 2022-02-23 | 2023-08-31 | Crinetics Pharmaceuticals, Inc. | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0173172B1 (ko) | 1992-12-17 | 1999-02-01 | 알렌 제이. 스피겔 | Crf 길항제로서의 피롤로피리미딘 |
| KR100421626B1 (ko) * | 1996-02-07 | 2004-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | Crf수용체에대한길항제로서의피라졸로피리미딘 |
| EA004403B1 (ru) * | 1996-07-24 | 2004-04-29 | Дюпон Фармасьютикалз Компани | Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения |
| DK0915880T3 (da) | 1996-07-24 | 2008-02-11 | Bristol Myers Squibb Pharma Co | Azolotriaziner og pyrimidiner |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| US6476038B1 (en) * | 1999-09-30 | 2002-11-05 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| ES2282401T3 (es) | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
| EP1697374B1 (en) * | 2003-12-22 | 2012-08-29 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
-
2007
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/sr unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 EP EP07842582A patent/EP2094709B1/en active Active
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en not_active Ceased
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
-
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
-
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081377A1 (es) | Compuestos de tiazol pirazolopirimidina | |
| CR9389A (es) | Compuestos de imidazopiridazina | |
| ES2299896T3 (es) | Derivados de benzazepina como antagonistas h3 de histamina. | |
| EA200801000A1 (ru) | Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf) | |
| EA200970302A1 (ru) | Тиофенпиразолопиримидиновые соединения | |
| IL210071A (en) | Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation | |
| MY161834A (en) | Substituted diazepan compounds as orexin receptor antagonists | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| PE20070093A1 (es) | Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c | |
| CR9622A (es) | Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3 | |
| EA200800992A1 (ru) | 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| EA200500172A1 (ru) | Азабициклопроизводные в качестве антагонистов мускариновых рецепторов | |
| PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| MX2008011576A (es) | Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos. | |
| EA200600688A1 (ru) | Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а | |
| EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора | |
| WO2004093789A3 (en) | Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| WO2006114666A8 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
| MXPA06000774A (es) | E3-nitro-pirazolo[1,5-a]pirimidinas 7-sustituidas y composiciones y metodos relacionados. | |
| TNSN05324A1 (en) | 7-substituted 3-nitro-pyrazolo `1,5-a! pyrimidines | |
| RO200800818A8 (ro) | Compus tetrapirolic nesimetric substituit - procedeu de obţinere şi evaluare biologică la nivel celular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |